Neucardin
Phase 3Small molecule
Neucardin is one of 16 small molecule programs targeting Systolic Heart Failure. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Systolic Heart Failure
#DrugCompanyPhaseTrials
1Simdax
Orion Corporation, Orion PharmaApproved
Aldactone
PfizerApproved
Niacor
AbbVieApproved
Farxiga
AstraZenecaApproved
Corlanor
AmgenApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Invokana
WWim Janssens
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glucophage
EMD SeronoApproved
Benemid
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Systolic Heart Failure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Neucardin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZensun Sci. & Tech. Co., Ltd.